Novo Nordisk to spend more on acquisitions and external innovation
The success of its GLP-1 molecule in recent years has led Novo Nordisk to increase its focus on acquisitions and external drug candidates and companies.
By Josefine Buur Bach, translated by catherine brett
Novo Nordisk's successful GLP-1 drug is creating new opportunities for the Danish pharmaceutical giant, which has stated it can no longer rely exclusively on drugs developed in-house, Danish financial daily Børsen reports.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
.jpg)
Novo Nordisk hires Queen Latifah for US marketing offensive
For subscribers
